PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Pregnancy mRNA Vaccination Cuts COVID-19 Hospitalisation by Half Across Europe

COVID-19 mRNA vaccineBNT162b2mRNA-1273boosterpregnancyvaccine effectivenesstarget trial emulationreal-world evidencehospitalisationwomen's healthEuropeobservational study Women's Health / Reproductive

Background Information

COVID-19 vaccines lower hospitalisation risk for pregnant women.

Understanding COVID-19 vaccine effectiveness in pregnant women aids in balancing maternal and fetal health during pandemics. Primary vaccination showed 55.6% effectiveness against hospitalisation, while booster provided 34.1% effectiveness. The study supports recommending mRNA COVID-19 vaccination during pregnancy for reducing hospitalisation risk. Data is more variable for infection prevention. mRNA COVID-19 vaccination during pregnancy reduces hospitalisation risk, with variable infection protection.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Mercadé-Besora N, Raventós B, Trinh NT, Li H, Hayati S, Giuliodori A, Burkard T, Burn E, Català M, Prieto-Alhambra D, Morales DR, Nyberg F, Marie Egeland Nordeng H, Duarte-Salles T

Citation: Mercadé-Besora N, Raventós B, Trinh NT, et al. Target trial emulation of effectiveness of COVID-19 mRNA vaccination during pregnancy in four European countries. Nature communications. 2026;17(1). doi:10.1038/s41467-026-78469-x

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.